皮里米迪尼尔化:对抗癌细胞毒性具有选择性
Rohina Alim1, Scott D Andrew1, Christopher J Parkinson1
1School of Dentistry and Medical Sciences, Charles Sturt University, NSW 2800, Australia.
Bioorganic & medicinal chemistry letters
|September 19, 2025
概括
新的pyrimidinyl hydrazones (PH) 通过结合金属和产生活性氧来显示强大的抗癌活性. 这些化合物对各种癌细胞系具有强烈的细胞毒性,对正常细胞的毒性最小,需要进一步研究.
科学领域:
- 药用化学 医学化学
- 癌症生物学 癌症生物学
- 无机化学 无机化学
背景情况:
- 胺基 (PH) 是一种具有潜在治疗应用的化合物类别.
- 金属离子在生物过程中起着至关重要的作用,它们的失调与癌症有关.
- 开发具有提高疗效和降低毒性的新型抗癌药物是一个重大挑战.
研究的目的:
- 为了合成和表征新型胺基酸 (PH).
- 为了评估PH的体外细胞毒性活动与各种人类癌症细胞系.
- 研究金属离子复合在PH的抗癌活性中的作用.
主要方法:
- 从二皮里米丁开始合成9种PH化合物.
- 在体外细胞毒性测定使用癌症和非癌症细胞系.
- 确定IC50值和评估毒性.
- 研究PH与铜,铁和离子的复合.
主要成果:
- PH化合物与铜,铁和离子表现出强烈的关联.
- 化合物15在体外对黑色素瘤,卵巢和胰腺癌细胞系表现出显著的细胞毒性 (IC50值为0.37,0.11,1.09微米).
- PH对非癌症MRC-5纤维细胞有极小的毒性 (在25μM没有毒性).
- PH的铜复合体表现出类似的细胞毒性,但对非癌细胞的毒性增加.
- 与单独的PH相比,铁复合物通常不会提高功效.
结论:
- 胺基是强大的金属化剂,在体外具有显著的抗癌活性.
- 作用机制可能涉及金属动员和反应性氧物种的产生.
- PH代表了一类有前途的抗癌药物,需要进一步进行广泛的研究.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
815
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
815
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
589
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
589
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
605
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
605
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


